Evaluating Cancer Costs in NCI Trials

  • Kevin A. Schulman
  • William L. BoykoJr.
Part of the Cancer Treatment and Research book series (CTAR, volume 97)


Historically, the evaluation of new, therapeutic strategies for cancer have depended exclusively on safety and clinical efficacy.[1] Today, there is an increasing recognition by health care providers and financing organizations of the resource constraints on the provision of these services, lending greater importance to their economic evaluation.[1][4] Further, as costs for such services continue to rise, there is also a heightened desire for information on the value for each dollar spent in providing these technologies.


Economic Evaluation Medical Bill Hospital Bill Health Care Financing Administration Direct Nonmedical Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schulman KA, Yabroff KR. Measuring the cost-effectiveness of cancer care. Oncology 1995; 9: 523–33.PubMedGoogle Scholar
  2. 2.
    Drummond MF, Stoddart GL, Torrance GW. Methods for Economic Evaluation of Health Care Programmes. New York: Oxford Medical Publications, 1987.Google Scholar
  3. 3.
    Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.Google Scholar
  4. 4.
    Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1991; 146:473–81.Google Scholar
  5. 5.
    NCI Economic Conference. 1994. The integration of economic outcome measures into NCI sponsored therapeutic trials. Bethesda, April 20–24.Google Scholar
  6. 6.
    NCI/ASCO Health Economics Working Group Workbook. Unpublished.Google Scholar
  7. 7.
    Eisenberg JM, Schulman KA, Glick HA, et al. Pharmacoeconomics: economic evaluation of Pharmaceuticals. In Pharmacoepidemiology (BL Strom ed). 2nd ed. Chincester, John Wiley & Sons, 1994.Google Scholar
  8. 8.
    Mauskopf J, Schulman K, Bell L, et al. A strategy for collecting phannacoeconomic data during phase II/III clinical trials. Pharmacoeconomics. 1996; 9(3): 264–77.PubMedCrossRefGoogle Scholar
  9. 9.
    Schulman K-A, Yabroff KR, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. Drug Inform J 1995; 29: 1405–14.Google Scholar
  10. 10.
    Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. J Am Med Assoc 1992; 269(15): 2055–61.CrossRefGoogle Scholar
  11. 11.
    Schulman KA, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with HIV infection. Ann Intern Med. 1991; 114: 798–802.PubMedGoogle Scholar
  12. 12.
    O’Brien, B. Economic evaluation of Pharmaceuticals: Frankenstein’s monster or vampire of trials? Med Care 1996; 34: DS99–DS108.PubMedGoogle Scholar
  13. 13.
    Schulman KA, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Controlled Clin Trials 1996; 17: 304–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Finkler, SA. Cost accounting for health care organizations: concepts and applications. Gaithersburg, Maryland: Aspen Publishers, Inc., 1994.Google Scholar
  15. 15.
    Health Care Financing Administration. December 2, 1995. Revisions to payment policies and adjustments to the relative value units under the physician fee schedule for calendar year 1995; final rule. Federal Register.Google Scholar
  16. 16.
    St. Anthony’s UB-92 Editor: A guide to Medicare billing. Falconer CB, ed. Reston, Virginia: St. Anthony Publishing, 1994.Google Scholar
  17. 17.
    Glick HA, Polsky D, Wilke RJ, et al. Pharmacoeconomic analysis of tirilazad mesylate in patients with subarachnoid hemorrhage. Unpublished manuscript.Google Scholar
  18. 18.
    American Medical Association. 1993. Physicians’ Current Procedural Terminology, CPT-4-94. American Medical Association; Chicago.Google Scholar
  19. 19.
    Luce BR, Manning WG, Siegel JE, et al. “Estimating costs in cost-effectiveness analysis.” In Cost-effectiveness in Health and Medicine, New York: Oxford University Press, 1996.Google Scholar
  20. 20.
    The RED BOOK. Medical Economics Data. Montvale, VA: Medical Economics Company, Inc., 1995.Google Scholar
  21. 21.
    Revicki D, Irwin D, Reblando J, et al. The accuracy of self-reported disability days. Med Care 1994; 32:401–404.PubMedCrossRefGoogle Scholar
  22. 22.
    Schulman KA, Glick HA, Yabroff KR et al. Introduction to clinical economics: assessment of cancer therapies. Monogr Natl Cancer Inst 1995; 19: 1–9.PubMedGoogle Scholar
  23. 23.
    Schulman KA, Dorsainvil D, Yabroff KR, et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplant for Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant 1998; 21:607–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Ihle JN. Biomedical and biological properties of interleukin-3: a lymphokine mediating the differentiation of a lineage of cells which includes prothymocytes and mast-like cells. J Immunol. 1983; 131: 282.PubMedGoogle Scholar
  25. 25.
    Goodman JW, Hall EA, Miller KL, et al. Interleukin-3 promotes erythroid burst formation in serum free cultures without detectable erythropoietin. Proc Nat Acad Sci, USA 1989; 128: 501–9.Google Scholar
  26. 26.
    Lopez AF, Dyson PG, To LB, et al. Recombinant human interleukin-3 stimulation ofhematopoiesis in humans: loss ofresponsiveness with differentiation in the neurtrophilic myeloid series. Blood 1988; 72: 1797–1804.PubMedGoogle Scholar
  27. 27.
    “American Nurses Association: 1994 average salaries.” In: Hospital and Health Care Report. Rochelle Park, NY: Wyatt Data Services.Google Scholar
  28. 28.
    National Association for Home Care. 1995. Basic Statistics About Home Care.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Kevin A. Schulman
    • 1
  • William L. BoykoJr.
    • 1
  1. 1.The Clinical Economics Research UnitGeorgetown University Medical CenterWashington, DC

Personalised recommendations